Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer - Drug Trials For Money

Active Comparator: Cohort A Control Treatment Arm

SBRT + gemcitabine + nab-paclitaxel

Drug: Nab-paclitaxel

Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

Drug: Gemcitabine

2′, 2′-difluoro 2’deoxycytidine, dFdC

Procedure: SBRT

Stereotactic Body Radiation Therapy

Experimental: Cohort A Experimental Treatment Arm 1

SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel + aldoxorubicin HCl + N-803

Biological: N-803

Recombinant human super agonist interleukin-15 (IL-15) complex

Drug: Aldoxorubicin HCl

Aldoxorubicin hydrochloride

Drug: Nab-paclitaxel

Drug: Gemcitabine

2′, 2′-difluoro 2’deoxycytidine, dFdC

Drug: Cyclophosphamide

2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Procedure: SBRT

Stereotactic Body Radiation Therapy

Experimental: Cohort A Experimental Treatment Arm 2

SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel+ aldoxorubicin HCl + N-803 + PD-L1 t-haNK

Biological: N-803

Recombinant human super agonist interleukin-15 (IL-15) complex

Drug: Aldoxorubicin HCl

Aldoxorubicin hydrochloride

Biological: PD-L1 t-haNK

PD-L1 t-haNK suspension for infusion

Drug: Nab-paclitaxel

Drug: Gemcitabine

2′, 2′-difluoro 2’deoxycytidine, dFdC

Drug: Cyclophosphamide

2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Procedure: SBRT

Stereotactic Body Radiation Therapy

Active Comparator: Cohort B Control Treatment Arm

Irinotecan liposome + 5-FU/leucovorin

Drug: 5-Fluorouracil

5-fluoro-2,4 (1H,3H)-pyrimidinedione

Drug: Leucovorin

L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt

Drug: Irinotecan liposome

Irinotecan hydrochloride trihydrate is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano[3′,4′:6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4’bipiperidine]-1′-carboxylate, monohydrochloride, trihydrate

Experimental: Cohort B Experimental Treatment Arm

SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel+ aldoxorubicin HCl + N-803 + PD-L1 t-haNK

Biological: N-803

Recombinant human super agonist interleukin-15 (IL-15) complex

Drug: Aldoxorubicin HCl

Aldoxorubicin hydrochloride

Biological: PD-L1 t-haNK

PD-L1 t-haNK suspension for infusion

Drug: Nab-paclitaxel

Drug: Gemcitabine

2′, 2′-difluoro 2’deoxycytidine, dFdC

Drug: Cyclophosphamide

2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Procedure: SBRT

Stereotactic Body Radiation Therapy

Experimental: Cohort C Experimental Treatment Arm

SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel + aldoxorubicin + N-803 + PD-L1 t-haNK

Biological: N-803

Recombinant human super agonist interleukin-15 (IL-15) complex

Drug: Aldoxorubicin HCl

Aldoxorubicin hydrochloride

Biological: PD-L1 t-haNK

PD-L1 t-haNK suspension for infusion

Drug: Nab-paclitaxel

Drug: Gemcitabine

2′, 2′-difluoro 2’deoxycytidine, dFdC

Drug: Cyclophosphamide

2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Procedure: SBRT

Stereotactic Body Radiation Therapy

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.